3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
6
Phase 3
2
Phase 1/2
2
Phase 1
2
Status
Terminated
1
Active not recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Lymphoid
2
Conditions
Lymphoma, Follicular
67
Lymphoma, Large B-Cell, Diffuse
66
Lymphoma, Non-Hodgkin
59
Leukemia, Lymphocytic, Chronic, B-Cell
49
Lymphoma
48
Lymphoma, Mantle-Cell
28
Lymphoma, B-Cell, Marginal Zone
23
Recurrence
16
Lymphoma, B-Cell
14
Burkitt Lymphoma
11
Neoplasms
7
Leukemia
6
Lymphoma, Large-Cell, Immunoblastic
5
Lymphoma, Large-Cell, Anaplastic
5
Waldenstrom Macroglobulinemia
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Myasthenia Gravis
3
Hematologic Diseases
3
Lymphoproliferative Disorders
2
Lymphatic Diseases
2
Immunoblastic Lymphadenopathy
2
Hodgkin Disease
2
Arthritis, Rheumatoid
2
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Opsoclonus-Myoclonus Syndrome
1
Neuroblastoma
1
Neoplasms by Histologic Type
1
Myelodysplastic Syndromes
1
Limb-girdle muscular dystrophy, type 2C
1
Leukemia, Myeloid, Acute
1
Interventions
Rituximab
2
Epoetin Alfa
2
Early Intervention, Educational
2
Dexamethasone
2
Darbepoetin alfa
2
Bortezomib
2
ponatinib
1
pegaspargase
1
isatuximab
1
ibrutinib
1
ibritumomab tiuxetan
1
ferrous sulfate
1
ferric gluconate
1
ferric carboxymaltose
1
cirmtuzumab
1
blinatumomab
1
asparaginase erwinia chrysanthemi recombinant
1
acalabrutinib
1
Vorinostat
1
Vincristine
1
Sucrose
1
Prednisone
1
Methotrexate
1
Melphalan
1
Lenalidomide
1
Imatinib Mesylate
1
Ifosfamide
1
Etoposide
1
Doxorubicin
1
Daunorubicin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 3
×
Lymphoproliferative Disorders
×
Rituximab
×
Clear all
NCT04529772
2026-03-31
ESCALADE
Acerta Pharma BV
Phase 3
Active not recruiting
611 enrolled
NCT02366663
2018-03-12
SPINOZA
City of Hope Medical Center
Phase 3
Terminated
3 enrolled
8 charts